Legislation - SB0793

Requiring a licensed health care provider, when issuing a standing order for an opioid overdose reversal drug, to allow an individual to choose any formulation of any opioid overdose reversal drug approved by the federal Food and Drug Administration; and prohibiting certain private and public entities that prescribe and dispense opioid overdose reversal drugs from being required to keep in stock and dispense all opioid overdose reversal drugs approved by the federal Food and Drug Administration.

Committees

Original:: Finance Click to view Recorded Media

Committee Testimony

Witness List

Details

Cross-filed with: HB0572

Introduced in a prior session as: SB0408 Session: 2024 Regular Session

Bill File Type: Regular

Effective Date(s): October 1, 2025

History

Legislation History
Chamber Senate Calendar Date 2/03/2025 Legislative Date 1/28/2025 Action First Reading Finance Proceedings
Chamber Calendar Date Legislative Date Action Text - First - Public Health - Opioid Overdose Reversal Drugs Proceedings
Chamber Senate Calendar Date 2/06/2025 Legislative Date 2/06/2025 Action Hearing 2/18 at 1:00 p.m. Proceedings

Chamber	Calendar Date	Legislative Date	Action
Senate	2/03/2025	1/28/2025	First Reading Finance
			Text - First - Public Health - Opioid Overdose Reversal Drugs
Senate	2/06/2025	2/06/2025	Hearing 2/18 at 1:00 p.m.

File Code

Subjects

Statutes